ESG Strategy and Materiality
- Process for Analysis and Identification of Materiality Topics
- Materiality Topics at Olympus
- Medium-term Goals and KPIs/Achievements
Olympus ESG strategies, which have been devised as part of management strategy, are implemented and managed based on the identified Materiality Topics.
Positioning of ESG in Our Company Strategy
In the company strategy announced in November 2025, Olympus sets out “Innovation-driven growth,” “Simplicity,” and “Accountability” as our three priorities. We will endeavor to build a strong and sustainable organization by working with regulators and stakeholders to remain a company with integrity and transparency. We will meanwhile actively aim to contribute to the realization of Our Purpose, namely of: “Making people’s lives healthier, safer and more fulfilling,” in order to become a leader in the healthcare industry as well as in ESG.
Furthermore, we have positioned the promotion of ESG as a key initiative under “Accountability” in the company strategy, and will enhance the affinity and consistency between our ESG Strategy and Olympus’s company strategy, business strategy, and functional strategy to levels greater than previously seen.
Process for Analysis and Identification of Materiality Topics
Since identifying four Materiality Topics in FY2020, we have conducted several reviews and made adjustments. In conducting these reviews and adjustments, we identified Six Focus Areas and 24 Materiality Topics falling under these Focus Areas, based on input from our stakeholders, societal expectations and requirements, trends within the MedTech industry, and analyses of risks and opportunities from the perspective of sustainability.
In the process of identifying these Materiality Topics, mapping of these topics onto the two axes of “importance to stakeholders” and “impact on Olympus's business (importance to Olympus)” is carried out, with Olympus then assigning these to three levels of priority: Top Priority, High Priority, and Others. KPIs have been set for those Materiality Topics that have been positioned as particularly important Top Priority topics, with progress towards their achievement being actively managed. Progress statuses and new initiatives are also actively discussed at ESG Committee and Board of Directors meetings.
Steps in the Analysis and Identification of Materiality Topics
Identification of Social Issues
Listing up of social issues based on an outside survey on changes in sustainability trends since previous identification, as well as various ESG-related frameworks and ESG survey assessment items.
Assignation of Priority to Social Issues by Importance to Stakeholders
Conducting interviews with medical institutions, government agencies, investors, and ESG assessment bodies. Assignation of priority to issues in terms of their importance to stakeholders
Assignation of Priority to Social Issues by Importance to Olympus
Assignation of priority to issues in terms of their impact on Olympus's business
Materiality Identification
Identification of materiality items through processes including deliberations by the Group Executive Committee and the Board of Directors (proposed and approved as part of company strategy). In addition, drafting of a Materiality Matrix with assigned priorities to the identified social issues from the perspective of the two axes.
Materiality Matrix
Materiality Topics at Olympus: Six Focus Areas and 24 Materiality Topics
The Six Focus Areas and 24 Materiality Topics are integral to Olympus’s corporate and business activities, and we will actively contribute to the resolution of a wide range of social issues through our activities related to these areas.
ESG Strategy Structure
List of the Six Focus Areas and 24 Materiality Topics
FY2026
Can be swiped left or right
| Six Focus Areas | 24 Materiality Topics | ||
|---|---|---|---|
| Top Priority (item) | High Priority (item) | Others (item) | |
| Healthcare Access and Outcome |
|
|
|
| Compliance, Product Quality and Safety |
|
|
|
| Responsible Supply Chain |
|
|
|
| Healthy Organization |
|
|
|
| Carbon Neutral Society and Circular Economy |
|
|
|
| Corporate Governance |
|
|
|
Medium-term Goals and KPIs/Achievements (Top Priority)
FY2026: Medium-term Goals and KPIs/Achievements (Top Priority)
We have established KPIs for each of the items positioned as Top Priorities, and are managing our progress toward achieving these.
Can be swiped left or right
| Six Focus Areas | Materiality Topics Positioned as Top Priorities | Medium-term Goals and KPIs | Achievements (FY2026) |
|---|---|---|---|
| Healthcare Access and Outcome |
|
CAGR +20% Colorectal cancer-related training in target emerging countries and regions | 84 programs (CAGR +105% compared to FY2024) |
| CAGR +20% Colorectal cancer-related online / hybrid training provided with HCPs globally | 87 programs (CAGR +22% compared to FY2024) |
||
| Compliance, Product Quality and Safety | Quality, safety and regulatory compliance in products, services and solutions | Timely ESG disclosures according to SASB Standards* * SASB Standards: Published by the Sustainability Accounting Standards Board (SASB; US) to encourage the standardization of non-financial information disclosure. Industry-specific disclosure standards have been formulated. |
Appropriate disclosure was done. Details shown in the following chart. |
| Responsible Supply Chain | Supply chain risk mitigation and resilience | Annual assessment/monitoring for multi-tier supply chain risks | Continued multi-tier supply chain risk assessment and monitoring across direct material suppliers through a digital platform. In FY2026, we further advanced supplier engagement in SCV, BCP, and ESG assessments, strengthening risk visibility and enabling more targeted mitigation. |
| Healthy Organization | Inclusion | 100% Eligible male employees in Japan* take parental leave by FY2026 * Olympus Corporation |
100.6% |
| Carbon Neutral Society and Circular Economy |
|
Net-zero: Net-zero GHG emissions across scope 1, 2 and 3 by FY2040 | GHG emissions (scope 1, 2 and 3): 859,311 t-CO2e (+22% compared to FY2020) Increased emissions compared with the base year due to growth in material procurement as sales expanded. Requested suppliers to measure their GHG emissions and set targets aligned with the SBTs to reduce emissions from suppliers, which account for the majority of emissions. Also continued initiatives to reduce emissions from logistics, such as direct delivery and the use of ships. |
| Carbon neutral: Net-zero GHG emissions (Scope 1 and 2) from our site operations by FY2031 | GHG emissions (scope 1 and 2): 29,566 t-CO2e (-76% compared to FY2020)
* Excluding the amount offset through carbon offsets, GHG emissions were reduced by 66% compared to FY2020. Implemented production process improvements and energy-saving initiatives that contribute to reducing CO2 emissions, and switched to fuels with lower CO2 emissions. Also significantly reduced emissions compared with the base year through long-term procurement of renewable energy via off-site corporate PPAs (power purchase agreements) and expanded use of electricity from renewable energy sources through green power certificates and other measures. |
||
| Corporate Governance | Corporate governance and reporting transparency | Enterprise Risk Management: applied consistently across the globe | Conducted Enterprise Risk Management based on “Olympus Group Risk Management and Crisis Response Policy” and relevant internal rules. The result was reported to the Group Executive Committee and Board of Directors |
Information Disclosure in Accordance with SASB Standards on Product Quality and Safety
Can be swiped left or right
| Code | Accounting Metric | Olympus Disclosure Information |
|---|---|---|
| SASB:HC-MS-250a.1 | Number of recalls issued, total units recalled | Appropriately disclosed on the websites of regulatory authorities in respective countries. Example: US FDA: Medical Device Recalls (fda.gov)  |
| SASB:HC-MS-250a.2 | Products listed in any public medical product safety or adverse event alert database | Appropriately disclosed in accordance with US FDA requirements. MedWatch:The FDA Safety Information and Adverse Event Reporting Program | FDA |
| SASB:HC-MS-250a.3 | Number of fatalities associated with products | Appropriately disclosed in accordance with US FDA requirements. MAUDE - Manufacturer and User Facility Device Experience (fda.gov) |
| SASB:HC-MS-250a.4 | Number of enforcement actions taken in response to violations of good manufacturing practices (GMP) or equivalent standards, by type | Appropriately disclosed on the following website. https://datadashboard.fda.gov/ora/cd/inspections.htm |
FY2027: Medium-term Goals and KPIs
Link to Activities Pages
Contributions to Society through Our Medical Business
This section presents examples of Olympus’s contributions to society through its medical business.
- Healthcare Access and Outcome
This section gives an overview of Olympus's activities in the medical business, including technology development to enable early diagnosis and minimally invasive treatments using endoscopy, and support for the training of physicians.
- Elevating the standard of care
This section presents Olympus's initiatives to elevate standards of healthcare, including educational support for healthcare professionals.
- For the Benefit of Patients
This section presents initiatives to improve patient care pathways (prevention to recuperation).
- Facts & Figures
This section presents various data illustrating the features and characteristics of Olympus.
- Global Healthcare Data
This PDF compiles and makes publicly available healthcare data, including case numbers for cancers and other diseases.